Company Filing History:
1 out of 1,835 
1 out of 5,111 
1 out of 4 
Years Active: 2016
Title: Jean-Antoine Ribeil: Innovator in β-Thalassemia Treatment
Introduction
Jean-Antoine Ribeil is a notable inventor based in Paris, France. He has made significant contributions to the field of medical research, particularly in the treatment of β-thalassemia. His innovative approaches have the potential to improve the lives of individuals afflicted with this genetic disorder.
Latest Patents
Jean-Antoine Ribeil holds a patent for "Methods and compositions for the treatment of β-thalassemia." This patent outlines methods and compositions that restore or increase erythrocyte maturation in individuals suffering from β-thalassemia by preventing the proteolysis of the GATA-1 protein. The patent also includes screening methods for identifying agents that bind to heat shock protein 70 (HSP-70) and inhibit HSP-70 α-globin binding, while allowing GATA-1 protein-HSP-1 binding in a manner that prevents GATA-1 proteolysis.
Career Highlights
Throughout his career, Jean-Antoine Ribeil has worked with prestigious institutions such as the Institut National de la Santé et de la Recherche Médicale and the Centre National de la Recherche Scientifique. His work has been instrumental in advancing research in hematology and genetic disorders.
Collaborations
Jean-Antoine has collaborated with esteemed colleagues, including Olivier Hermine and Genevieve Courtois. These collaborations have further enriched his research and contributed to the development of innovative treatments.
Conclusion
Jean-Antoine Ribeil's contributions to the treatment of β-thalassemia highlight his role as a leading inventor in the medical field. His innovative methods and collaborations continue to pave the way for advancements in healthcare.